Literature DB >> 553832

[3-Hydrazinepyridazine derivatives. III. Synthesis and anti-hypertensive activity of new 3-(2-acylhydrazine)-pyridazine-6-alkylamino substitutes].

F Parravicini, G Scarpitta, L Dorigotti, G Pifferi.   

Abstract

The synthesis of 2-(6-dialkylamino-3-pyridazinyl)hydrazinecarboxylates (II) and hydrazides (V) from the corresponding 3-chloro-6-dialkylaminopyridazines (I) is described. The 6-substituted derivatives of 2,3-dihydro-1,2,4-triazolo[4,3-b]pyridazine-3-ones (III) and 1,2,4-triazolo[4,3-b)pyridazines (VI) were obtained by thermal cyclization of (II) and (V), respectively. The new acyl derivatives were evaluated together with todralazine and budralazine as antihypertensive agents in comparison with propildazine and hydralazine. The ethoxycarbonyl compound [(II g), ISF 2469] exhibits good antihypertensive activity particularly via oral administration. Its interesting pharmacodynamic properties, including slow onset and long-lasting action, qualify it for further pharmacological and clinical studies.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 553832

Source DB:  PubMed          Journal:  Farmaco Sci        ISSN: 0430-0920


  4 in total

1.  Cadralazine did not produce the SLE-syndrome when hydralazine did.

Authors:  O K Andersson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Studies on the metabolism of cadralazine in rat.

Authors:  L Simonotti; M Zanol; F Parravicini; G Pifferi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

3.  [14C]cadralazine: absorption, distribution and excretion in rat and dog.

Authors:  G Bonardi; E Rossi; M Pellegatti
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

4.  Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.

Authors:  M Catalano; J Parini; M Romano; A Libretti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.